Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05024994 · OUTCOME

Median Overall Survival

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers · Source last updated 2026-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
1 year

What was measured

To assess the 1 year Overall Survival (OS)

Groups in this outcome

E7820

Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered. E7820: 100mg of E7820 QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
E782012

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
E78203.8Not reported1.512Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.5
        upper Limit
        12
        value
        3.8
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
To assess the 1 year Overall Survival (OS)
dispersion Type
95% Confidence Interval
groups
  1. description
    Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered. E7820: 100mg of E7820 QD
    id
    OG000
    title
    E7820
param Type
MEDIAN
reporting Status
POSTED
time Frame
1 year
title
Median Overall Survival
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice